Research
Hormonal
GLP-1 reduces glucagon and slows gastric emptying (GE), while GIP increases glucagon and does not alter GE.
Understanding the distinct effects of GLP-1 and GIP can inform treatment strategies for obesity.
StrongSupportsmedium confidence
However, GLP‐1 reduces glucagon and slows GE, whereas GIP increases glucagon and does not alter GE.
Why this rating
The abstract summarizes findings from a review, indicating a comprehensive analysis.
Source
Incretin impact on gastric function in obesity: physiology, and pharmacological, surgical and endoscopic treatments
Michael Camilleri · The Journal of Physiology · 2024
DOI 10.1113/jp287535
reviewCited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →